Comparative Pharmacology
Head-to-head clinical analysis: NEULASTA versus ZARXIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEULASTA versus ZARXIO.
NEULASTA vs ZARXIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegfilgrastim is a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF) conjugated to polyethylene glycol. It binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to specific cell surface receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after cytotoxic chemotherapy and at least 14 days before next cycle.
5 mcg/kg subcutaneously once daily. Round to nearest vial size (300 mcg/0.5 mL or 480 mcg/0.8 mL).
None Documented
None Documented
Terminal elimination half-life is approximately 15-23 hours (mean ~18 hours) in healthy subjects, allowing for once-per-cycle dosing for chemotherapy-induced neutropenia.
Terminal elimination half-life is approximately 3.5-4.5 hours in healthy adults; prolonged in renal impairment (up to 40 hours in end-stage renal disease).
Primarily renal clearance (through glomerular filtration and proteolytic degradation). Approximately 80% of the dose is eliminated renally as degraded peptides.
Primarily renal (70-80% as unchanged drug) via glomerular filtration; biliary/fecal excretion is negligible (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor